Recruiting OBSERVATIONAL NCT05543447

DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device (REheal)

DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device for Intracranial Aneurysms

Sponsor: Acandis GmbH

Conditions Flow Diverter Intracranial Aneurysm

Interventions Flow Diverter Treatment with DERIVO 2 Heal Embolisation Device

Updated 7 times since 2022 Last updated: Aug 27, 2025 Started: Dec 15, 2022 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05543447, this observational or N/A phase trial focuses on Flow Diverter and Intracranial Aneurysm and remains actively recruiting participants. Sponsored by Acandis GmbH, it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Oct 2025 — Present [monthly]

Recruiting
Sep 2025 — Oct 2025 [monthly]

Recruiting
Jan 2025 — Sep 2025 [monthly]

Recruiting
Sep 2024 — Jan 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting

▶ Show 2 earlier versions

Mar 2023 — Jul 2024 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Mar 2023 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acandis GmbH

Data source: Acandis GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augsburg, Germany , Berlin, Germany , Bremerhaven, Germany , Cologne, Germany , Dresden, Germany , Düsseldorf, Germany , Essen, Germany , Frankfurt am Main, Germany , Halle, Germany , Hamburg, Germany and 6 more locations